Feb 27 Pacira Pharmaceuticals Inc said
a late-stage trial testing its drug Exparel for a wider use
showed the treatment significantly reduced pain compared to
placebo in knee surgery patients.
Exparel is already approved for use in managing
post-surgical pain when administered directly at the site of the
pain. The latest trial was testing Exparel's efficacy when
applied to a major nerve adjacent to the site of the surgery,
thereby blocking any sensation until the nerve endings.
A late-stage trial testing the drug, Exparel, showed that
patients taking the medicine experienced significant reduction
in pain over 72 hours.